,sentence,pubmed_id,content,label,labeler
0,"5 ||| Participants ||| 2.5 ||| Exclusion criteria included diastolic BP of less than 95 mm Hg, known history of diabetes mellitus (fasting glucose, Ն140 mg/dL or random glucose, Ͼ200 mg/ dL), urinary protein to creatinine ratio of more than 2.5, accelerated or malignant hypertension within 6 months, secondary hypertension, evidence of non-BP-related causes of chronic kidney disease, serious systemic disease, clinical congestive heart failure, or specific indication for or contraindication to a study drug or study procedure.",12435255," Exclusion criteria included diastolic BP of less than 95 mm Hg, known history of diabetes mellitus (fasting glucose, Ն140 mg/dL or random glucose, Ͼ200 mg/ dL), urinary protein to creatinine ratio of more than 2.5, accelerated or malignant hypertension within 6 months, secondary hypertension, evidence of non-BP-related causes of chronic kidney disease, serious systemic disease, clinical congestive heart failure, or specific indication for or contraindication to a study drug or study procedure.",po.Disease,lingtaiwei
1,"14 ||| Participants ||| 2.14 ||| Three primary treatment comparisons were specified: lower vs usual BP goal, ramipril vs metoprolol, and amlodipine vs metoprolol.",12435255,"Three comparisons were specified: lower vs usual BP goal, ramipril vs metoprolol, and amlodipine vs metoprolol.",i.Procedure,lingtaiwei
2,"12 ||| Participants ||| 2.12 ||| Based on a 3ϫ2 factorial design, participants were randomized equally to a usual mean arterial pressure goal of 102 to 107 mm Hg or to a lower mean arterial pressure goal of 92 mm Hg or lower, and to treatment with 1 of 3 antihypertensive drugs (a sustainedrelease ␤-blocker, metoprolol, 50 to 200 mg/d; an angiotensin-converting enzyme inhibitor, ramipril, 2.5 to 10 mg/d; or a dihydropyridine calcium channel blocker, amlodipine, 5 to 10 mg/d).",12435255," antihypertensive drugs (a sustainedrelease ␤-blocker, metoprolol, 50 to 200 mg/d; an angiotensin-converting enzyme inhibitor, ramipril, 2.5 to 10 mg/d; or a dihydropyridine calcium channel blocker, amlodipine, 5 to 10 mg/d",i.Diagnostic,lingtaiwei
3,38 ||| Participants ||| 2.38 ||| The relationships of the treatment comparisons with baseline proteinuria were investigated by adding con- tinuous interaction terms between ln (urinary protein to creatinine ratio) and the treatment groups.,12435255, adding continuous interaction terms between ln (urinary protein to creatinine ratio) and the treatment groups.,i.Procedure,lingtaiwei
4,"116 ||| RESULTS ||| 3.63 ||| Nevertheless, our data suggest that once BP is lowered to a given level, additional risk factors are important in patients with chronic kidney disease resulting from hypertension.",12435255,additional risk factors are important,o.Treatment,lingtaiwei
5,118 ||| RESULTS ||| 3.65 ||| This is consistent with the Modification of Diet in Renal Disease results that showed a favorable trend for the lower BP goal in participants with baseline proteinuria of higher than 1 gram per day but not at lower levels of proteinuria.,12435255,results that showed a favorable trend,o.Treatment,lingtaiwei
6,"124 ||| RESULTS ||| 3.71 ||| Secondary analyses also suggest that metoprolol may improve renal outcome compared with amlodipine, particularly in participants with higher proteinuria.",12435255,metoprolol may improve renal outcome,o.Treatment,lingtaiwei
7,135 ||| RESULTS ||| 3.82 ||| Our results do support recommendations that angiotensin-converting enzyme inhibitors should be considered as first line therapy over ␤-blockers and dihydropyridine calcium channel blockers in these patients.,12435255,angiotensin-converting enzyme inhibitors should be considered as first line therapy over,o.Treatment,lingtaiwei
8,4 ||| Participants ||| 2.4 ||| The African American Study of Kidney Disease and Hypertension (AASK) prospectively addressed 2 questions in patients with hypertensive nephrosclerosis.,12435255,hypertensive nephrosclerosis.,pr.Disease,lingtaiwei
